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Summary
Background: Atherosclerosis is an inflammatory disease in which a perpetuated activation of
NFkappaB via the RAGE (receptor for advanced glycation end products)-MAPK signalling pathway
may play an important pathogenetic role. As recently S100 proteins have been identified as ligands
of RAGE, we sought to determine the effects of the proinflammatory heterodimer of S100A8/
S100A9 on the RAGE-NFkappaB mediated induction of proinflammatory gene expression.
Methods: Human umbilical vein endothelial cells (HUVEC) were preincubated for 72 h with AGE-
albumin or unmodified albumin for control, whereas AGE-albumin induction resulted in an
upregulation of RAGE. Following this preactivation, cells were stimulated for 48 h with
heterodimeric human recombinant S100A8/S100A9.
Results: Heterodimeric S100A8/S100A9 enhanced secretion of IL-6, ICAM-1, VCAM-1 and MCP1
in AGE-albumin pretreated HUVEC in a dose dependent manner. These effects could not be
detected after stimulation with the homodimeric proteins S100A8, S100A9, S100A1 and S100B.
The effects of heterodimeric S100A8/S100A9 were reduced by inhibition of the MAP-kinase
pathways ERK1/2 and p38 by PD 98059 and SB 203580, respectively.
Conclusion: The heterodimeric S100A8/S100A9 might therefore play a hitherto unknown role in
triggering atherosclerosis in diabetes and renal failure, pathophysiological entities associated with a
high AGE burden. Thus, blocking heterodimeric S100A8/S100A9 might represent a novel
therapeutic modality in treating atherosclerosis.
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Introduction
In recent years atherosclerosis has been identified as an
inflammatory disease[1]. Animal experiments indicate
that the RAGE (receptor of advanced glycation end prod-
ucts)/MAPK (mitogen activated protein-kinases)/NF-kap-
paB signal transduction pathway might play a critical role
in perpetuating inflammatory responses[2]. RAGE is a
member of the superfamily of immunoglobulin-like
receptors and one of the receptors for AGEs[3]. After AGE
binding to RAGE, NF-kappaB is activated via MAP-
kinases, which in turn leads to an upregulation of several
proatherogenic factors. In contrast to other signal trans-
duction pathways RAGE induces a sustained activation of
NF-kappaB[4]. The engagement of RAGE by AGE proteins
may be considered as the 'first hit' in a two-stage model,
in which the second phase of cellular perturbation is
mediated by superimposed accumulation of modified
lipoproteins, invading bacterial pathogens, ischemic
stress and other factors[3].
Recently members of the EF-hand Ca2+ binding protein
family S100 were identified as ligands of RAGE[5,6]. At
present 21 different S100 proteins are known[7], which
are differentially expressed in several tissues exhibiting
regulatory properties on a variety of cellular processes.
Interestingly, in several metabolic, inflammatory and neo-
plastic diseases a differential expression of S100 proteins
was observed, that is thought to play an important role in
the pathogenesis of breast cancer, Alzheimer's disease,
inflammatory bowel disease and transplant rejection[8].
Under the variety of S100 proteins S100A8 and S100A9
are expressed in neutrophils and monocytes[9] in which
they represent a large proportion of the cytosolic pro-
tein[10]. S100A8/S100A9 are also known uneder a variety
of alternative names like MRP-8/MRP-14, calprotectin,
and calgranulin A/calgranulin B[8]. Activated neutrophils
and monocytes play a central role in the initiation and
progression of atherosclerosis. After activation of these
cells S100A8 and S100A9 are released into the extracellu-
lar compartment via a tubulin dependent pathway[11],
where they are known to promote the adhesion of neu-
trophils to endothelium, to act as chemotractants on
monocytes and to enhance the uptake of LDL cholesterol
by macrophages[12]. Moreover, elevated serum levels of
S100A8 and S100A9 were reported in several inflamma-
tory diseases like cystic fibrosis[13], inflammatory bowel
disease[14], rheumatoid arthritis[15] and HIV infec-
tion[16].
Given these molecular findings we sought to determine
whether proatherosclerotic and proinflammatory actions
of S100A8 and S100A9 are involved in NF-kappaB
dependent signalling.
Materials and methods
Materials
Human recombinant S100A8 and S100A9 was obtained
from BMA Biomedicals (Switzerland). S100A8 and
S100A9 are known to form heterodimers predominantly
und physiological conditions[17]. The heterodimeriza-
tion was performed by mixing both proteins in an equi-
molar solution containing 10mM Tris-HCl, pH 7.4, 0,1%
sodium cholate, 1 mM EDTA, 1 mM 2-mercaptoethanol.
Thereafter CaCl2 from a stock solution was added until a
concentration of 2 mM and incubated under ambient
temperature for 10 minutes. The efficiency of this proce-
dure was assessed using a heterodimer specific ELISA
(BMA, Switzerland). Endotoxin was removed using
DetoxiGel™ columns (Pierce, Rockford, IL, USA), which
was confirmed by the E-Toxate assay (Sigma, St. Louis,
MO, USA) employing limulus amebocyte lysate. Het-
erodimeric S100A8/S100A9 was stored in aliquots at -
20°C. SB 203580 and PD 98059 were obtained from Cal-
biochem (CA, USA).
Generation of AGEs
The generation of AGEs was performed as described[18].
Bovine serum albumin (100 g/l) was dissolved in phos-
phate buffered saline (pH 7.4) containing 0.5 M glucose,
1 mM PMSF, 2.5 mM EDTA, 100U/ml penicillin und 100
mg/l streptomycin and incubated under sterile conditions
at 37°C for 6 weeks and then stored at -80°C. Mixtures of
non-glycated bovine serum albumin and glucose of the
same preparation were immediately frozen at -80°C and
served as negative controls. These albumin-glucose solu-
tions are referred to in the following as controls. The activ-
ity of AGE-preparations was confirmed using the one
stage clotting assay as previously described[19], which is
based on the induction of tissue factor on the surface of
endothelial cells.
Endothelial cell culture
Human umbilical cords were obtained from the depart-
ment of obstetrics after informed consent in accordance
with the ethical standards as formulated in the Helsinki
declaration. Endothelial cells were harvested enzymati-
cally as described[20] and were maintained in RPMI 1640
medium (Life Sciences, Germany) containing 20% fetal
calf serum (Biochrom, Germany), 5 mM L-glutamine, 0.1
% Penicillin/Streptomycin, 25 mM HEPES, 50 U/ml
heparin, 50 mg/l endothelial growth factor. For all exper-
iments, cells of passage 3 were kept in RPMI 1640
medium containing 5% FCS for 24 h after confluence.
Prestimulation of HUVEC was performed with a 1 mg/l
concentration of AGE-preparations or albumin-glucose
for controls. Except for the dose-response curves, S100
proteins were used for all experiments in an 1 µM (24 µg/
ml heterodimeric S100A8/S100A9) concentration. CellCardiovascular Diabetology 2006, 5:6 http://www.cardiab.com/content/5/1/6
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viability was assessed by exclusion of trypan blue and cell
counting in a hemocytometer.
Immunoblotting
Whole cell lysates were prepared by sonification of cell
pellets in a buffer containing 10 mM HEPES pH 7.9, 10
mM KCL, 0,1 mM EGTA, 0,1 mM EDTA, 1 mM DTT, 0,5
mM PMSF. Protein concentration was determined using
the DC Protein Assay (BioRad, Munich, Germany). Equal
amounts (50 µg protein per lane) were resolved by 12 %
SDS-PAGE using Novex 12% gels (Invitrogen, CA, USA)
and transferred to PVDF membranes (Millipore, MA,
USA). Immunoblots were developed using 1:2500 mono-
clonal mouse anti-RAGE (MAB5328 Chemicon, CA, USA)
emloying the Western-Light PlusTM chemiluminescent
detection kit (Tropix, Bedford, MA, USA).
ELISA
ELISA kits for IL-6, ICAM-1 and VCAM-1 were purchased
from Diaclone (Besancon, France), ELISA for MCP-1 from
Biosource (CA, USA). All measurements were performed
according to the manufacturer's guidelines.
NF-kappaB ELISA
Both preparation of nuclear extracts by the mini extraction
method and measurement of NF-kappa B on microtiter
plates employing anti-NFκB c-Rel (Santa Cruz Biotech-
nology, CA, USA) was performed according to Sch-
reiber[21].
Statistical analysis
All values are expressed as mean ± standard deviation.
Comparison between two groups was performed using
the unpaired student T test employing the SPSS statistics
software. A p-value below 0.05 was considered as signifi-
cant.
Results
As generation of AGEs is critically dependent to enviro-
mental conditions like pH, protein concentration and var-
ious other unknown factors, we tested our AGE
preparation for its functionality using the established "one
stage clotting assay", which is dependent on activation of
tissue factor. Our AGE preparation significantly decreased
clotting time indicating increased tissue factor activation
(Fig. 1a). In contrast, the heterodimeric S100A8/S100A9
protein neither exhibited significant activation of clotting,
nor did it show any effect on the expression of RAGE. AGE
proteins, however, induced the expected upregulation of
RAGE on HUVEC after 48 h of stimulation (Fig. 1b).
HUVEC were stimulated with S100 proteins for 48 hours.
Without AGE-preincubation, S100A8/S100A9 did not
exhibit any effect on HUVEC regarding the release of IL-6,
sICAM-1 and sVCAM-1. After preincubation with AGE
proteins for 72 hours, however, stimulation with het-
erodimeric S100A8/S100A9 resulted in a marked increase
of IL-6, sICAM-1 and sVCAM-1 measured in cell culture
supernatants (Fig. 2a–c). These effects were not seen with
two other members of the S100 family, S100A1 and
S100B. Only MCP-1 release was significantly increased by
S100A8/S100A9 irrespective of previous AGE stimulation
(Fig. 2d). The dose-response curves for S100A8/S100A9
shows that AGE preincubation sensitizes HUVEC for the
effects of lower concentrations of S100A8/S100A9 (Fig.
3a). In contrast, increasing concentrations of S100A8/
S100A9 did not show any effect on IL-6 concentrations in
controls, while AGE prestimulation resulted in a dose
dependent effect of S100A8/S100A9 (Fig. 3b).
Heterodimeric S100A8/S100A9 was generated by coincu-
bation of both recombinant proteins in the presence of 2
a) One stage clotting assay: AGE stimulation of HUVEC  resulted in enhanced tissue factor expression indicated by a  reduction of clotting time Figure 1
a) One stage clotting assay: AGE stimulation of HUVEC 
resulted in enhanced tissue factor expression indicated by a 
reduction of clotting time. Activation of the tissue factor 
pathway was not observed with S100A8/S100A9 alone. * p < 
0.05 as compared to control and S100A8/S100A9. b) Immu-
noblot showing upregulation of RAGE upon AGE stimulation 
in HUVEC. S100A8/S100A9 had no effect, while costimula-
tion by AGE and S100A8/S100A9 exhibited no additional 
effect (not shown). The doubled bands are probably due to 
degradation of RAGE.
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mM calcium. On these conditions heterodimers are rap-
idly formed, as confirmed by ELISA specific for the het-
erodimeric isoform (not shown). To confirm the
specificity of the effects seen with heterodimeric S100A8/
S100A9, recombinant homodimeric forms of S100A8 and
S100A9 from the same preparation were used for differen-
tial stimulation experiments. While only the het-
erodimeric S100A8/S100A9 preparation showed effects
on IL-6 release (Fig. 4a), no effects were seen for the
respective homodimers. This was also the case for MCP-1,
sICAM-1 and sVCAM-1 (not shown). Activation of the
nuclear factor-kappa B (NF-kB) subunit cRel was only
induced by the heterodimeric S100A8/S100A9 molecule
(Fig. 4b), while both homodimers again showed no effect.
In order to identify the involved MAP-kinase pathways,
we performed blocking experiments with inhibitors of the
Erk1/2 and p38 pathways, as these are known to be
involved in RAGE dependent signalling[2]. Addition of
only one of the two MAPK-inhibitors PD 98059 or SB
203580 resulted in a moderate decrease of IL-6 concentra-
tion or NF-kappaB activation after S100A8/S100A9 stim-
ulation, whereas a combination of both inhibitors
decreased proinflammatory activation even below control
levels (Figure 5). These data strongly suggest that the
observed effects are dependent on both MAP-kinase path-
ways and that blocking of only one of these pathways can
be at least partially compensated by the other pathway.
Because blocking experiments with kinase inhibitors can
be influenced by unspecific effects of these agents, we
used phospho-specific antibodies, which specifically
detect the activated forms of Erk1/2 and p38. After AGE
preincubation, stimulation of HUVEC with S100A8/
S100A9 resulted in rapid activation of Erk1/2 and p38
Stimulation of HUVEC by various S100 proteins for 48h after 72h preincubation with AGEs or albumin-glucose for control:  Only after AGE pretreatment, 1 µM S100A8/S100A9 (24 µg/ml) induced a marked increase of IL-6 Figure 2
Stimulation of HUVEC by various S100 proteins for 48 h after 72 h preincubation with AGEs or albumin-glucose for control: 
Only after AGE pretreatment, 1 µM S100A8/S100A9 (24 µg/ml) induced a marked increase of IL-6 (a), sICAM-1 (b) and 
sVCAM-1 (c). MCP-1 (d) release was induced by S100A8/S100A9 irrespective of AGE pretreatment. 1 µM of S100A1 or 
S100B exhibited no effect.
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within 15 minutes (Figure 6). Compared to controls with-
out AGE preincubation, S100A8/S100A9 had no signifi-
cant effects on MAP-kinase activation.
Discussion
The activation of proinflammatory signalling pathways by
RAGE is considered as one important pathogenetic feature
in the initiation of atherosclerosis, especially in condi-
tions in which RAGE-ligands accumulate such as in diabe-
tes mellitus and chronic renal failure[22]. The
engagement of RAGE by AGEs, a heterogeneous group of
glycoxidated proteins, was proposed as a "first hit" in a
two stage model of inflammation. Several factors are dis-
cussed to be involved in the "second hit", including oxi-
dized lipoproteins and bacterial pathogens[3]. Since
S100B and EN-RAGE (S100A12), proteins of the S100/
calgranulin family, are known to interact with RAGE[5,6],
the aim of our study was to evaluate, whether the proin-
flammatory S100 proteins S100A8 and S100A9, being
expressed and secreted by mononuclear cells, would
enhance activation of the RAGE/NF-kappaB axis thus pro-
viding a novel proatherogenetic mechanism.
AGE proteins
The term AGEs describes a large group of heterogeneous
molecules, which are formed by glycoxidation processes,
depending on enviromental conditions[23,24]. Imitating
the in vivo process, AGEs can be generated in-vitro by
incubation of protein solutions with glucose under oxy-
gen atmosphere at 37°C. These AGEs vary in their compo-
sition and molecular properties. Although this might be a
disadvantage in contrast to purified single AGE com-
pounds like Nepsilon- carboxy-methyl-lysine (CML) from
the biochemical view, this model employing a mixture of
Stimulation of IL-6 (a) and NF-kappaB (b) by S100A8/S100A9  heterodimers but not with S100A8 or S100A9 homodimers Figure 4
Stimulation of IL-6 (a) and NF-kappaB (b) by S100A8/S100A9 
heterodimers but not with S100A8 or S100A9 homodimers. 
In controls, neither heterodimers nor homodimers were 
applied.
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AGE pretreatment sensitized HUVEC for the stimulatory 
effects of S100A8/S100A9 regarding MCP-1 (a). Dose 
dependency of S100A8/S100A9 effects on IL-6 in AGE prein-
cubated HUVEC (b). Similar results were obtained for 
sICAM-1 and sVCAM-1 (not shown).
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AGEs is much closer to pathophysiologial conditions
found in vivo and observed in diabetes mellitus. The func-
tional activity of the AGEs preparations used were con-
firmed by activated clotting induced in endothelial cells
and augmented RAGE expression confirmed by Western
blot (Fig. 1). Importantly, activation of clotting was nei-
ther seen with the potential RAGE ligands S100A8 and
S100A9, nor with other S100 proteins.
Preactivation of HUVEC by AGEs
For a better discrimination of AGE and S100 effects, the
preincubation of HUVEC with AGEs was terminated after
three days, when HUVEC monolayers were washed to
remove AGEs. Furthermore, the AGE concentration (1 µg/
l) used in our study was markedly lower as compared to
other studies, in which up to 600 µg/l were used[25]. Con-
sequently, no differences in proinflammatory activation
were seen between AGE preincubated cells and albumin-
glucose controls at baseline (data not shown). Upon
induction with S100A8/S100A9, however, a marked dif-
ference was seen between AGE prestimulated and control
cells, as only HUVEC sensitized by AGEs showed a signif-
icant proinflammatory response, evidenced by increased
cytokine release, adhesion molecules, MAP kinase and
NF-kappa B cRel activation. Interestingly, the only excep-
tion in our setting of experiments was MCP-1, which was
released after S100A8/S100A9 stimulation irrespective of
whether cells were preincubated with AGEs or not, imply-
ing that receptors different from RAGE and/or other AGE-
binding sites are involved in S100A8/S100A9 dependent
MCP-1 expression. However, dose response curves
revealed, that AGE treated HUVEC exhibited a stronger
inflammatory response to lower concentrations of
S100A8/S100A9 with respect to MCP-1 release. As MCP-1
mediated activation and migration of monocytes plays a
central role in the initiation of atherosclerosis[26] as well
as in the development of restenosis after angioplasty[27],
the proinflammatory stimulation of endothelial cells by
heterodimeric S100A8/S100A9 protein may thus repre-
sent a hitherto unknown critical mechanism in the early
propagation of atherosclerosis.
Differential effects of hetero- and homodimers
Control experiments revealed that stimulation of HUVEC
with various homodimeric S100 proteins (S100A1,
S100B, S100A8, S100A9) does not result in any proin-
flammatory activation. These data not only underscore
that proinflammatory effects of heterodimeric S100A8/
S100A9 were specific in our experimental setting, but also
add evidence to the specific physiological properties of
this dimeric molecule. In acute and activated chronic
inflammation the heterodimeric S100A8/S100A9 was
found to be the predominant isoform[15], exhibiting
molecular characteristics that are clearly distinguishable
from both homodimeric isoforms[17]. In this context it
has been speculated that either the heterodimeric protein
forms an epitope, that specifically interacts with defined
cellular receptors, or only the formation of heterodimeric
S100A8/S100A9 would allow the bridging of two differ-
ent epitopes[28,29]. Interestingly, Kerkhoff et al showed
that only the heterodimer is able to bind arachidonic acid
with high affinity resulting in a complex that interacts
with CD36 facilitating fatty acid uptake by endothelial
cells[30]. This finding sheds new light on the link between
The proinflammatory effect of 1 µM heterodimeric S100A8/ S100A9 on AGE pretreated HUVEC was reduced by block- ers of the MAP-kinases Erk1/2 (PD98059) and p38 (SB  203580) Figure 5
The proinflammatory effect of 1 µM heterodimeric S100A8/
S100A9 on AGE pretreated HUVEC was reduced by block-
ers of the MAP-kinases Erk1/2 (PD98059) and p38 (SB 
203580). Combined blocking of both MAP-kinases resulted in 
complete inhibition of NF-kappaB activation (a) and IL-6 
release (b).
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S100A8/S100A9 and RAGE, as recently RAGE overexpres-
sion was shown to be associated with an enhanced COX-
2 expression in atherosclerotic plaques of diabetic
patients[31].
Potential receptors for S100A8/S100A9
As many authors employ soluble RAGE (sRAGE) to con-
trol for RAGE specific effects it might appear as a limita-
tion, that we did not include any such experiments to our
study. There is however ample evidence that control
experiments using sRAGE certainly do not control for
RAGE specific effects. They much more underscore the
concept that RAGE ligands represent a group of multire-
ceptor ligands whereas the employment of sRAGE simply
sequesters those ligands thereby preventing their interac-
tion with other receptors in addition to RAGE. Interest-
ingly studies in RAGE-/- mice demonstrate that the
protection conferred by RAGE deficiency is lower than
that mediated by sRAGE. Moreover RAGE-/- mice can be
protected by sRAGE in certain settings of adaptive
immune response implying that abounding RAGE ligands
may overwork the RAGE pathway and coactivate other
receptors (for review see [32]) it is against this background
that there still is a controversial debate as far as the
endothelial receptors of S100A8/S100A9 are concerned.
S100A8/S100A9 was reported to bind to heparan sulfate
glycosaminoglycans on a human microvascular endothe-
lial cell line (HMEC-1)[33], that neither expresses CD36
nor RAGE. In contrast, Hofmann et al showed that
S100A12, which is a close homologue of S100A9, clearly
binds to RAGE on HUVEC consequently activating a
proinflammatory axis via NF-kappaB[5], while Srikrishna
et al. [34] found that S100A8/S100A9 binds to carboxy-
lated N-glycans, which are components of RAGE. It is
therefore conceivable that heterodimeric S100A8/S100A9
is a ligand that binds to various cell receptors giving rise to
a differentiated downstream signalling. The latter is fur-
ther implied by the differential gene activation described
Stimulation of AGE-pretreated (black squares) HUVEC with heterodimeric S100A8/S100A9 resulted in phosphorylation of  both MAP kinases p38 (e) and Erk1/2 (k) within 15 minutes Figure 6
Stimulation of AGE-pretreated (black squares) HUVEC with heterodimeric S100A8/S100A9 resulted in phosphorylation of 
both MAP kinases p38 (e) and Erk1/2 (k) within 15 minutes. Representative immunoblots for AGE preincubated HUVEC are 
shown for phosphorylated p38 (a), total p38 (b), phosphorylated Erk1/2 (f) and total Erk1/2 (g). Control experiments: Phos-
phorylated p38 (c), total p38 (d), phosphorylated Erk1/2 (h) and total Erk1/2 (i) *p < 0.05 AGE pretreatment vs. albumin-glu-
cose (open circles) for control.
min
i)
k)
h)
d)
c)
Ctrl. 0 15 30 60 120
n
-
f
o
l
d
 
E
r
k
1
/
2
p
h
o
s
p
h
o
r
y
l
a
t
i
o
n
0
1
2
3
4
5
6
7
8
*
Ctrl. 0 15 30 60 120
n
-
f
o
l
d
 
p
3
8
 
p
h
o
s
p
h
o
r
y
l
a
t
i
o
n
min e)
0
1
2
3
4
5
6
7
*
control
AGE preincub.
g)
f)
b)
a)Cardiovascular Diabetology 2006, 5:6 http://www.cardiab.com/content/5/1/6
Page 8 of 9
(page number not for citation purposes)
in the present study, demonstrating that S100A8/S100A9
induces MCP-1 release in the absence of AGEs, while pres-
timulation with AGEs evokes S100A8/S100A9 mediated
release of ICAM, VCAM and IL-6.
Signalling pathways
RAGE dependent inflammatory processes mainly recruit
MAP kinases p38 and Erk1/2[2] and a downstream activa-
tion of the transcription factor NF-kappaB[4] for induc-
tion of proinflammatory and procoagulatory gene
expression. As demonstrated here, stimulation of HUVEC
by S100A8/S100A9 critically depends on these two MAP
kinases, since blocking of both pathways completely abol-
ished the proinflammatory effects. In a recently published
study using oligonucleotide microarray technology, stim-
ulation of human microvascular endothelial cells with
200 µg/ml heterodimeric S100A8/S100A9 was shown to
result in an upregulation of several genes that are known
to promote platelet aggregation, inflammation, and
endothelial permeability[35]. As cardiovascular events
can be precipitated by acute respiratory infections[36], an
increase of S100A8/S100A9 blood levels during acute
infection in diabetic patients with increased RAGE expres-
sion and sustained NF-kappaB activation within athero-
sclerotic plaques might be an attractive molecular
explanation for the excess morbidity and mortality in dia-
betes. Given these results, blocking of S100A8/S100A9
effects might thus represent a novel therapeutic strategy in
the prevention or reversal of atherosclerotic complica-
tions especially in Diabetes mellitus or chronic renal fail-
ure.
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